<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03867942</url>
  </required_header>
  <id_info>
    <org_study_id>LG-GSCL006</org_study_id>
    <nct_id>NCT03867942</nct_id>
  </id_info>
  <brief_title>BE Study of Bilayer Combination of Gemigliptin/Rosuvastatin 50/20mg in Comparison to Monolayer Combination.</brief_title>
  <official_title>Randomized, Open-label, Single Dose, Two-way Crossover Clinical Trial to Investigate the Pharmacokinetics/Pharmacodynamics, Safety, and Tolerability of the Monolayer Drug in Comparison to the Bilayer Drug Administered in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Chem</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Chem</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate and compare PK/PD, safety and tolerability of monolayer combination of
      Gemigliptin/Rosuvastatin 50/20mg and bilayer combination of Gemigliprin/Rosuvastatin 50/20mg
      in healthy adults.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate and compare Pharmacokinetics/Pharmacodynamics, safety and tolerability of
      monolayer combination of Gemigliptin/Rosuvastatin 50/20mg in comparison to bilayer
      combination of Gemigliprin/Rosuvastatin 50/20mg administered in healthy volunteers
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 21, 2019</start_date>
  <completion_date type="Anticipated">August 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 24, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gemigliptin AUC</measure>
    <time_frame>0hour(pre-dose), 0.5hour, 1hour, 1.5hour, 2hour, 3hour, 4hour, 5hour, 6hour, 8hour, 12hour, 24hour, 48hour, 72hour</time_frame>
    <description>Gemigliptin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rosuvastain AUC</measure>
    <time_frame>0hour(pre-dose), 0.5hour, 1hour, 1.5hour, 2hour, 3hour, 4hour, 5hour, 6hour, 8hour, 12hour, 24hour, 48hour, 72hour</time_frame>
    <description>Rosuvastain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rosuvastain Cmax</measure>
    <time_frame>0hour(pre-dose), 0.5hour, 1hour, 1.5hour, 2hour, 3hour, 4hour, 5hour, 6hour, 8hour, 12hour, 24hour, 48hour, 72hour</time_frame>
    <description>Rosuvastain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gemigliptin Cmax</measure>
    <time_frame>0hour(pre-dose), 0.5hour, 1hour, 1.5hour, 2hour, 3hour, 4hour, 5hour, 6hour, 8hour, 12hour, 24hour, 48hour, 72hour</time_frame>
    <description>Gemigliptin</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Dyslipidemias</condition>
  <arm_group>
    <arm_group_label>monolayer group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>monolayer of Gemigliptin/Rosuvastatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bilayer group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>bilayer of Gemigliptin/Rosuvastatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Monolayer group</intervention_name>
    <description>Monolayered combination of gemigliptin and rosuvastatin</description>
    <arm_group_label>bilayer group</arm_group_label>
    <arm_group_label>monolayer group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bilayer group</intervention_name>
    <description>Bilayered combination of gemigliptin and rosuvastatin</description>
    <arm_group_label>bilayer group</arm_group_label>
    <arm_group_label>monolayer group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 19~45

          -  Body weight: 55kg or higher(female: 50kg or higher) and BMI 18~27kg/m2

          -  SBP 90~150mmHg, DBP 60-95mmHg

          -  Fasting glucose 70~120mg/dL

          -  Infertility

               1. Surgically infertile

               2. To prevent pregnancy, participants who agreed using 2 or more contraceptive
                  methods. Such as

          -  Barrier methods: Condom, Diaphragm, Cervical cap (Pessary), Spermicide

          -  Hormonal methods: Pills, Injection (Depot), Skin patch, Hormonal implant (Implanon),
             Vaginal ring

          -  Intrauterine Devices (IUDs): Cooper IUD (Loop), Hormonal IUD (Mirena)

          -  Natural methods: Basic body temperature, Ovulation period, Coitus interruptus,
             Abstinent

          -  People who perfectly understood clinical trial and independently decided to
             participate in clinical trial.

          -  People who will be able to collect blood sample during clinical trial period.

          -  People who are suitable to participate clinical trial by physical examination, lab
             test and medical examination by interview.

        Exclusion Criteria:

          -  Genetic problems such as galactose intolerance, Lapp lacatase deficiency,
             glucose-galactose malabsorption

          -  Clinically significant disease such as liver, kidney, digestive, pulmonary, endocrine
             system, cardiovascular disease etc.

          -  People who have gastrointestinal disease or history of surgery which would affect
             absorption of drug.

          -  History of clinically significant drug induced hyper-sensitive reaction or drug
             related muscular disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>kyungsang Yoo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>songyi Park</last_name>
    <phone>+82-2-6987-4195</phone>
    <email>songyi-park@lgchem.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>hyejin Yoon</last_name>
    <phone>+82-2-6987-4155</phone>
    <email>lgclinical@lgchem.com</email>
  </overall_contact_backup>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 6, 2019</study_first_submitted>
  <study_first_submitted_qc>March 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2019</study_first_posted>
  <last_update_submitted>March 6, 2019</last_update_submitted>
  <last_update_submitted_qc>March 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

